summerschool2017_2
bitmap
Agenda
Requirements

The “Approaches for developing anti-Leishmania vaccines” summer school consists of theoretical/practical sessions aiming to provide an overview on leishmaniasis with a focus on the knowledge related to preclinical vaccine development. 


The following Topics will be treated in the Summer School:
- Burden of the disease; 
- Pathogenesis;
- Human and Canine leishmaniasis; 
- Vector and Reservoir;
- Chemotherapy;
- Diagnosis and Biomarkers;
- Animal models;
- Vaccine strategies;
- Regulatory aspects in vaccine development.

Lectures will be held in English.

COURSE LOCATION

The course will be conducted at I3S, Porto, Portugal, from 25 to 29 September 2017. Free lunch and free coffee break will be provided according to the programme. 
The other meals and the accommodation will be at participants’ own expenses. 
A list of suitable hotels with a special rate for the summer school attendees will be provided to the participants upon request.
No attendance fees are required. 

The Announcement of the Summer School on Approaches for developing anti-Leishmania vaccines, are available at the address www.mulevaclin.eu 

How to apply
Applicants are invited to send their CV at the following email address: summerschool@mulevaclin.eu

The closing date for receipt of applications is 08 September 2017. 


Receipt of your CV will be acknowledged within two working days after receipt. CV not acknowledged as received may have not been successfully transmitted and should be resubmitted. 


Applicants are fully responsible for ensuring that their CV are received and acknowledged prior to the deadline. If an application is not received by the deadline, it will not be acknowledged and therefore not reviewed.


The evaluation and selection of candidates will be performed by the Course Selection Panel who will shortlist a maximum of 15 candidates on the basis of their application and reference. A short telephone interview may be held with the shortlisted candidates and members of the Course Selection Panel in order to select the final participants.


Elegibility Criteria

To be eligible to attend the course, candidates must be working in an European Union or Associated Member State, or be working in a project funded by the European Commission.  Participants should have experience dealing within any aspect of tropical medicine, parasitology, global health or vaccine development, as well as those who can demonstrate that the course would be of benefit to them and their organization. Candidates should also possess a BSc or MSc, or have demonstrable global health-related research experience.
In addition all applicants must provide a letter of reference from their supervisor.


Admission
Admission to the Summer School on Approaches for developing anti-Leishmania vaccines will take place after the evaluation of the curricula presented by each applicant before the deadline of 08 September 2017. 
Qualifications in the following categories shall be evaluated: 
University diplomas and other academic degrees; 
Specialization certificates and Professional qualifications;
Other diplomas; 

Notification
The organize committee will notify all selected applicants by email until 11 of September.

Organizing Committee
Anabela Cordeiro da Silva, IBMC, I3S, Portugal
Joana Tavares, IBMC, I3S, Portugal
Nuno Santarém, IBMC, I3S, Portugal
Pedro Cecílio IBMC, I3S, Portugal
Javier Moreno, ISCIII, Spain
Luigi Gradoni, Istituto Superiore di Sanità, Italy
José Maria Requena, UAM, Spain
Epifanio Fichera, Etna Biotech , Italy
Reinhard Glueck, Etna Biotech, Italy

Speakers
Anabela Cordeiro da Silva, IBMC and I3S, Portugal
Anna Olson, IBMC and I3S, Portugal
Epifanio Fichera, ETNA Biotech, Italy 
Eugenia Carrillo, ISCIII, Spain 
Jan Willem van der Laan (to be confirmed)
Javier Moreno, ISCIII, Spain
Jerome Estaquier, CNRS, France
Joana Tavares, IBMC and I3S, Portugal
José Maria Requena, UAM, Spain 
Luigi Gradoni, Istituto Superiore di Sanità, Italy 
Luiz Fabiano Oliveira, NIH, USA
Nuno Santarém, IBMC and I3S, Portugal
Pedro Cecilio, IBMC and I3S, Portugal
Ricardo Silvestre, ICVS, Portugal

Contact
Etna Biotech S.r.l. 
Via V. Lancia 57, 
95121 Catania, Italy
Tel/FAX +39 0 Carla Lima 95 2500276 
e-mail: info@etnabiotech.it - www.etnabiotech.it
e-mail: info@mulevaclin.eu - www.mulevaclin.eu
mulevaclin.eu | all rights reserved
Create a website